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SUMMARY – Multiple sclerosis (MS) is a chronic demyelinating neurologic disorder that ma-
inly affects young individuals (aged 20 to 50 years). Approximately 85% of patients experience an 
initial course with relapses and remissions (relapsing-remitting multiple sclerosis). Guidelines for the 
management of MS should be focused on three main areas: (a) the diagnosis of MS; (b) treatment 
of relapses; and (c) long-term preventive treatment including clinical follow up, dose adjustment, 
drug switch, control of therapeutic efficacy, and disease progression. Diagnosis should be established 
according to clinical and paraclinical criteria. Discussion on therapeutic recommendations is focu-
sed on the disease-modifying agents in acute phases and drugs for long-term treatment and sympto-
matic treatment. Differential diagnoses must be taken into account on making the diagnosis of MS. 
Therefore, diagnosis of MS should be established on clinical and radiological diagnostic criteria, 
cerebrospinal fluid analysis and evoked potentials.
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Clinical Evaluation
The signs and symptoms of multiple sclerosis (MS) 
may resemble those of other conditions; therefore diag-
nosis continues to be largely clinical, which determines 
the need to apply diagnostic criteria. Clinical diagnosis 
requires complete medical history and neurological ex-
amination. patients with MS, particularly on the first 
visit, should be examined carefully with special dedi-
cation. Neurologists treating these patients must have 
extensive experience in the management of MS. The 
Kurtzke Expanded Disability Status Scale (EDSS) is 
a method of quantifying disability in MS. The EDSS 
quantifies disability in eight Functional Systems (FS) 
and allows neurologists to assign a Functional System 
Score (FSS) in each of these. The Functional Systems 
are: pyramidal, cerebellar, brainstem, sensory, bowel 
and bladder, visual, cerebral, and others (Table 1). 
Table 1. EDSS steps 1.0 to 4.5 refer to people with multiple sclerosis (MS) who are fully ambulatory. EDSS steps 5.0 to 
9.5 are defined by impairment to ambulation (FS, Functional Systems)
 Kurtzke Expanded Disability Status Scale
0.0 Normal neurological examination
1.0 No disability, minimal signs in one FS
1.5 No disability, minimal signs in more than one FS
2.0 Minimal disability in one FS
2.5 Mild disability in one FS or minimal disability in two FS
3.0 Moderate disability in one FS, or mild disability in three or four FS; fully ambulatory
3.5 Fully ambulatory but with moderate disability in one FS and more than minimal disability in several others
4.0 Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite relatively severe dis-ability; able to walk without aid or rest some 500 meters
4.5
Fully ambulatory without aid, up and about much of the day, able to work a full day, may otherwise have 
some limitation of full activity or require minimal assistance; characterized by relatively severe disability; 
able to walk without aid or rest some 300 meters
5.0 Ambulatory without aid or rest for about 200 meters; disability severe enough to impair full daily activities (work a full day without special provisions)
5.5 Ambulatory without aid or rest for about 100 meters; disability severe enough to preclude full daily activi-ties
6.0 Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 100 meters with or without resting
6.5 Constant bilateral assistance (canes, crutches, braces) required to walk about 20 meters without resting
7.0 Unable to walk beyond approximately five meters even with aid, essentially restricted to wheelchair; wheels self in standard wheelchair and transfers alone; up and about in wheelchair some 12 hours a day
7.5 Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; wheels self but cannot carry on in standard wheelchair a full day; may require motorized wheelchair
8.0 Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of bed itself much of the day; retains many self-care functions; generally has effective use of arms
8.5 Essentially restricted to bed much of the day; has some effective use of arms; retains some self care func-tions
9.0 Confined to bed; can still communicate and eat
9.5 Totally helpless bed patient; unable to communicate effectively or eat/swallow
10.0 Death due to MS
Acta Clin Croat,  Vol. 51,  No. 1,  2012 119
Vanja Bašić Kes et al. Recommendations for diagnosis and management of multiple sclerosis
EDSS is gold standard in evaluating disability in 
MS patients, but it is criticized for placing too much 
emphasis on the use of legs and being insensitive to 
clinical change. Still, it has an important role in the 
evaluation of disease progression because many of 
magnetic resonance imaging (MRI) lesions are clini-
cally silent (without symptoms)1. However, in centers 
with trained staff, it is recommended to apply MS 
Functional Composite scale (MSFC) as accurate 
measurement of three dimensions at the same time, 
i.e. leg function/ambulation, arm/hand function and 
cognitive functions in MS patients. Standard MSFC 
includes three testing categories: Timed 25 foot walk 
Test, 9 Hole peg Test, and paced Auditory Serial Ad-
dition Test (pASAT 3“). One of the difficulties that 
neurologists most frequently have in clinical applica-
tion of this scale is the administration of the paced 
Auditory Serial Addition Test (pASAT) that requires 
a series of complex calculations. Some of the experts 
suggest replacing the pASAT with the Symbol Digit 
Modalities Test in such patients. The quality of life 
in MS patients should be evaluated by means of SF-
36 scale, at adequate intervals, as determined by the 
treating neurologist. Beck depression scale should be 
administered in order to evaluate mood disorders and 
Visual Analog Scale (VAS) in order to evaluate pain 
in MS patients (if it is present)2.
Cerebrospinal Fluid Analysis
Analysis of CSF should be included in the work-
up of MS suspected patient. The presence of oligo-
clonal bands through isoelectric focusing should be 
obtained. This technique is specific and sensitive; on 
the contrary, the use polyacrylamide gel may yield up 
to 50% of false-negative results. Another useful cere-
brospinal fluid (CSF) test to diagnose MS is the im-
munoglobulin G index. 
CSF analysis was one of the main paraclinical di-
agnostic criteria for MS (it is mandatory in the 2010 
revision of McDonald criteria for MS); nowadays, it 
is of great importance in differential diagnosis of MS 
(Table 2)3,4. 
Evoked Potentials
Visual evoked potentials (Eps) are useful in con-
firming the involvement of the optic nerve in case of 
diagnostic uncertainty, and to identify subclinical ab-
normalities at the onset of the disease. In patients with 
established optic neuritis, visual Eps add no informa-
tion. The technique of choice is checkerboard stimu-
lation; Eps to flash provide little information and are 
not useful, except for patients with severe visual field 
restriction. As abnormal findings are permanent, vi-
sual Eps are not useful for patient follow up. Eps are 
not included in the 2010 revised McDonald criteria 
for MS as paraclinical criteria (Table 2). 
Neuroimaging
The McDonald criteria as revised by polman and 
colleagues have introduced changes in the demonstra-
tion of dissemination in time and space through MRI, 
with subsequent key revisions with respect to the use 
and interpretation of imaging criteria. This has made 
conventional MRI (cMRI) the most important para-
clinical tool in diagnosing MS and establishing prog-
nosis at the clinical onset of the disease. These are the 
main reasons why cMRI findings have a major role 
in the revised diagnostic criteria for MS. The Con-
sortium of Multiple Sclerosis Centers issued guide-
lines on the most appropriate MRI technique. These 
include obtaining weighted images at T1 and T2 with 
gadolinium contrast, sagittal section at T2, coronal 
section to examine the optic nerve, sagittal section to 
view the spinal cord, and sagittal section to compare 
it with the lesions observed elsewhere. If any of the 
lesions are dubious, 0.5-mm slices must be obtained. 
Although it is recommended to use 1.5 tesla scanners, 
where such equipment is not available, the experts 
consider that MRI scans with lower resolution are 
equally useful for diagnosis. In centers with magne-
tization transfer (MT) capabilities, these images may 
aid diagnosis, although there are no standards and lon-
gitudinal follow up with MT MRI is difficult in daily 
clinical practice. Despite the sensitivity of cMRI for 
detecting MS lesions, the correlation between cMRI 
metrics (i.e. hyperintense lesions on T2- and post-
contrast T1-weighted images, hypointense lesions 
on T1-weighted images, and atrophy measurements) 
and clinical findings of MS is still limited. Amongst 
the likely reasons for this clinical/MRI discrepancy, 
a major one is the low pathological specificity of the 
abnormalities seen on cMRI scans and the inability 
of cMRI metrics to detect and quantify the extent of 
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Table 2. Polman’s revision of McDonald multiple sclerosis criteria 2010
Clinical presentation Additional data needed for MS diagnosis
≥2 attacksa ; objective clinical evi-
dence of ≥2 lesions or objective
clinical evidence of 1 lesion with 
reasonable historical evidence of
a prior attackb
Nonec
≥2 attacksa; objective clinical evi-
dence of 1 lesion
Dissemination in space, demonstrated by:
≥1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS (periventricu-
lar, juxtacortical, infratentorial, or spinal cord)d; or 
await a further clinical attacka implicating a different CNS site
1 attacka; objective clinical evidence 
of ≥2 lesions
Dissemination in time, demonstrated by:
simultaneous presence of asymptomatic gadolinium-enhancing and non 
enhancing lesions at any time; or
a new T2 and/or gadolinium-enhancing lesions(s) on
follow up MRI, irrespective of its timing with reference to a baseline scan; or
await a second clinical attacka
1 attacka; objective clinical evidence 
of 1 lesion (clinically isolated syn-
drome) 
Dissemination in space and time, demonstrated by: 
for DIS: ≥1 T2 lesion in at least 2 of 4 MS-typical regions of the CNS 
(periventricular, juxtacortical, infratentorial, or spinal cord)d; or 
await a second clinical attacka implicating a different CNS site; and 
for DIT: simultaneous presence of asymptomatic gadolinium-enhancing and 
non enhancing lesions at any time; or
a new T2 and/or gadolinium-enhancing lesions(s) on
follow up MRI, irrespective of its timing with reference to a baseline scan; or
await a second clinical attacka
Insidious neurological progression 
suggestive of MS (ppMS)
1 year of disease progression (retrospectively or prospectively determined) 
plus 2 or 3 following criteriad:
evidence for DIS in the brain based on ≥1 T2 lesions in the MS-charac-1. 
teristic (periventricular, juxtacortical or infratentorial) regions
2. evidence for DIS in the spinal cord based on ≥2 T2 lesions in the cord
3. positive CSF (isoelectric focusing evidence of oligoclonal bands and/or 
elevated IgG index)
a An attack (relapse, exacerbation) is defined as patient-reported or objectively observed events typical of an inflammatory demyelinating event in 
the CNS, current or historical, with duration of at least 24 hours, in the absence of fever or infection. It should be documented by contemporane-
ous neurological examination, but some historical events with symptoms and evolution characteristic of MS, but for which no objective neuro-
logical findings are documented, can provide reasonable evidence of a prior demyelinating event. Reports of paroxysmal symptoms (historical or 
current) should, however, consist of multiple episodes occurring over not less than 24 hours. Before a definitive diagnosis of MS can be made, 
at least 1 attack must be corroborated by finding on neurological examination, visual evoked potential response in patients reporting prior visual 
disturbance, or MR consistent with demyelination in the area of the CNS implicated in the historical report of neurological symptoms.
b Clinical diagnosis based on objective clinical findings for 2 attacks is most secure. Reasonable historical evidence for 1 past attack, in the absence 
of documented objective neurological findings, can include historical events with symptoms and evolution characteristic of a prior inflammatory 
demyelination event; at least 1 attack, however, must be supported by objective findings.
c No additional tests are required. However, it is desirable that any diagnosis of MS be made with access to imaging based on these Criteria. If 
imaging or other tests (for instance, CSF), are undertaken and are negative, extreme caution needs to be taken before making a diagnosis of MS, 
and alternative diagnoses must be considered. There must be no better explanation for the clinical presentation, and objective evidence must be 
present to support the diagnosis of MS.
d Gadolinium-enhancing lesions are not required; symptomatic lesions are excluded from consideration in subjects with brainstem or spinal cord 
syndromes.
 MS = multiple sclerosis; CNS = central nervous system; MRI = magnetic resonance imaging; DIS = dissemination in space; DIT = dissemination 
in time; ppMS = primary progressive multiple sclerosis; CSF = cerebrospinal fluid; IgG = immunoglobulin G.
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Table 3. Differential diagnosis12
Underlying pathology Clinical diagnosis Main recommended work-up
Vascular
Cerebral autosomal dominant ar-
teriopathy with subcortical infarcts 
and leukoencephalopathy (CADA-
SIL)
Lacunar infarcts
Leukoencephalopathies
Vasculitis
Fabry disease
Family history of neurologic disorders
CSF analysis
Brain MRI scan
Carotid Doppler ultrasound
Echocardiogram
Blood and urine testing
Genetic tests
Infectious
(CNS involvement) Brucellosis
Brucella culture in CSF
Antibody detection (microagglutination,
Coombs or Bengali rose)
CSF analysis
Brucellosis confirmed at another body site
Cysticercosis
Echinococcosis
ELISA in blood and CSF
Western blot (immunoelectrotransfer)
in blood and CSF
Neurotrophic viruses
ELISA
Western blot
Immunofluorescence
particle agglutination
Virus detection (polymerase chain reaction (pCR) 
testing)
Borrelia burgdorferi
Syphilis
Listeria
ELISA
Western blot
Immunofluorescence
Immune
Systemic lupus erythematosus
Sarcoidosis
Histiocytosis
Serology with antinuclear antibody and anti-dsDNA 
serum and urine ACE, CD4/CD8, whole body gallium 
imaging, bronchoalveolar lavage analysis
Isolated CNS vasculitis Autoantibodies (immunology)Angiography
Metabolic Vitamin B12 deficiency
Abnormal blood test results: low serum B12, methyl-
malonic acid and homocysteine concentrations, antipa-
rietal cells (ApS)
Malnutrition 
General clinical examination
Toxic agents
Abnormal blood test results
General clinical examination
Toxicology for metals 
Hematologic Thrombophilia
Inherited: C and S proteins, gene mutations for coagu-
lation factor II,V and pAI I 
(pCR testing) 
Acquired: according to presumptive diagnosis
Tumors primary and secondary expansive processes of the CNS
History
General clinical examination
Brain MRI scan
Tumor markers
CSF = cerebrospinal fluid; ELISA = enzyme-linked immunosorbent assay; MRI = magnetic resonance imaging.
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damage in normal-appearing brain tissues (NABTs). 
These inherent limitations of cMRI have prompted 
the development and application of modern quanti-
tative MR techniques [MR spectroscopy (1H-MRS), 
MT MRI, diffusion-weighted (DW) MRI and func-
tional MRI (fMRI)] to the study of MS. Although 
these techniques have provided important insight into 
the pathobiology of MS, their practical value in the 
assessment of MS patients in clinical practice has yet 
to be realized5-7.
Diagnosis of Multiple Sclerosis
Over time, different sets of criteria have been de-
veloped to support the diagnosis of MS in clinical 
practice. Historically, most relevant have been those 
proposed by Schumacher and colleagues, poser and 
colleagues, and McDonald and colleagues. The revi-
sions to the McDonald criteria made by polman and 
colleagues are the currently used criteria for the diag-
nosis of MS (Table 2)8-11.
If the Criteria are fulfilled and there is no better 
explanation for the clinical presentation, the diagnosis 
is „MS“; if suspected, but the Criteria are not com-
pletely met, the diagnosis is „possible MS“; if another 
diagnosis arises during the evaluation that better ex-
plains the clinical presentation, then the diagnosis ins 
„not MS“.
Clinically Isolated Syndrome
The concept of clinically isolated syndrome (CIS) 
was developed following polman and colleagues’ revi-
sion of the McDonald criteria. The term is used to 
describe the first acute neurological episode lasting for 
more than 24 h, caused by inflammation or demyeli-
nation at one or more central nervous system (CNS) 
sites, i.e. monofocal or multifocal CIS. There are dif-
ferent MRI diagnostic criteria for CIS. These criteria 
have changed over time and must be correlated with 
clinical manifestations. Recently, the European mul-
ticenter network for the study of MS through MRI 
scans (MAGNIMS) has proposed new criteria for 
dissemination in time and space, as well as a diag-
nostic algorithm to predict the conversion of CIS into 
clinically defined MS13,14.
CIS can be divided into 5 subtypes:
type 1: clinically monofocal, at least one asymptom-
atic lesion on brain MRI
type 2: clinically multifocal, at least one asymptom-
atic lesion on brain MRI
type 3: clinically monofocal, brain MRI normal, 
without any lesion 
type 4: clinically multifocal, brain MRI normal, 
without any lesion
type 5: without clinical manifestation suggestive of 
demyelinating disease, brain MRI suggestive 
of demyelinating disease (radiologically iso-
lated syndrome, RIS)12.
Radiological Isolated Syndrome (RIS)
The widespread availability of MRI as an imag-
ing diagnostic test has led to the incidental finding 
of white matter lesions at the CNS that are sugges-
tive of MS and not attributable to any other disease 
in asymptomatic patients. These lesions are known as 
‘radiological isolated syndrome’. The natural history of 
these lesions and the evolution of these patients re-
garding their risk of developing MS are unclear, and 
further evidence is required to establish this risk15.
Neuromyelitis Optica
It is of great importance to distinguish neuromy-
elitis optica (NMO) from MS because of its differ-
ent course and prognosis and putative differences in 
response to immunomodulatory therapy. NMO is 
the most commonly seen non-MS idiopathic inflam-
matory demyelinating disease (IIDD). It has been 
distinguished in the past from MS by the restricted 
manifestations such as optic neuritis and myelitis, 
and for having a monophasic, not relapsing course. 
However, recent studies suggest that NMO is usu-
ally a relapsing IIDD, overlapping in clinical course 
with MS. Normal brain imaging and longitudinally 
extensive cord lesions in the context of acute myelitis 
have helped distinguish NMO from MS. A recently 
discovered, highly specific and moderately sensitive 
serum biomarker NMO-IgG is useful for the diag-
nosis of NMO. The following should be taken into 
account on distinguishing NMO from MS:
– NMO is most commonly a relapsing disorder, and 
hence that characteristic is not useful to distin-
guish it from MS;
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– the key clinical difference is NMO predilection 
for severe episodes of myelitis that often but not 
always manifest as a complete transverse myelitis, 
and for severe episodes of optic neuritis, often but 
not always with incomplete recovery; 
– the myelitis, unlike that which occurs in MS, is 
usually accompanied in the acute phase by a T2-
weighted spinal cord lesion extending over three 
or more spinal segments (longitudinally extensive 
transverse myelitis, LETM), which may be hy-
pointense on T1-weighted MRI and also associ-
ated with varying degrees of gadolinium enhance-
ment;
– usually, there is no brain involvement in NMO, 
and brain MRI is often normal, particularly in the 
early stages of the disease;
– if present, brain lesions generally do not fulfill 
typical criteria for dissemination in space (usually 
presented in regions with high expression of aqua-
porin 4, including the hypothalamus, medulla, 
and other brainstem areas);
– oligoclonal bands or elevated IgG index in CSF 
are detected in 10%-20% of patients with NMO 
compared with 70%-90% of patients with MS; 
and
– limited syndromes of NMO can be presented with 
recurrent transverse myelitis alone accompanied by 
long spinal cord lesions or recurrent optic neuritis 
alone, and are seropositive for NMO-IgG. Such 
spatially limited syndromes should not be quali-
fied as NMO, even in the presence of a positive 
NMO-IgG serum assay. The subsequent develop-
ment of optic neuritis in a patient with myelitis or 
vice versa may permit a later diagnosis of NMO12.
Acute Disseminated Encephalomyelitis
Historically, acute disseminated encephalomyelitis 
(ADEM) was distinguished from MS by its mono-
phasic course and encephalopathy or coma in com-
bination with multifocal symptoms (e.g., cerebellar 
signs, cerebral motor or sensory features, optic neuritis 
or myelitis) characteristic of an IIDD, often follow-
ing an infectious illness. MRI typically shows usually 
symmetric multifocal or diffuse brain lesions. Some 
patients experience recurrence of their initial ADEM 
symptoms with reactivation of the same MRI lesions 
as were present at the time of the initial illness ap-
pearance (recurrent ADEM-RDEM). Although 
characteristics such as encephalopathy with multifo-
cal symptoms may be more likely for ADEM than 
for MS, no clinical, paraclinical or imaging criteria 
reliably distinguish fulminant initial episodes of MS 
from ADEM, therefore follow up of such patients and 
differential work-up is of great importance. Diagno-
sis of ADEM should be made in patients with a first 
event compatible with demyelinating disease that is 
acute or subacute in onset (over days to weeks), with a 
stable or stuttering course, but only when additional 
characteristics are present, e.g., encephalopathy mani-
fested either as altered level of consciousness, behav-
Table 4. Diagnostic algorithm when MS is suspected
Clinical signs and symptoms
 
typical                     atypical
clinical evaluation 
differential diagnosis
diagnostic work-up
   
CIS, RIS NMO, ADEM, OTHER
Diagnosis according to revised McDonald 
criteria60%-90% risk for MS 20% risk for MS
ACUTE TREATMENT
FOLLOW UP
MS, NMO, RDEM, OTHER
TREATMENT OF RELAPSES
LONG TERM TREATMENT
MS = multiple sclerosis; NMO = neuromyelitis optica; 
ADEM = acute disseminated encephalomyelitis; 
CIS = clinically isolated syndrome; 
RIS = radiologically isolated syndrome; 
RDEM = recurrent disseminated encephalomyelitis
 
 
 
 


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ioral change, or altered cognitive functioning. New 
symptoms may emerge over intervals up to 3 months 
from onset without intervening remission (but not be-
yond 3 months; RDEM). If remission of the initial 
symptoms occurs, followed by new symptoms after 
an interval of 1 month, the diagnosis of MS is more 
likely than ADEM.
The presence of multiple supra- or infratento-
rial lesions in combination with lesions of deep grey 
nuclei and at least one lesion greater than 1-2 cm in 
diameter is characteristic of brain MRI in ADEM 
patients. Spinal cord lesions may or may not be pres-
ent, but when present, they tend to be longitudinally 
extensive12.
Treatment
Treatment of relapses as well as long term treat-
ment should be planned according to the results of 
clinical trials and evidence based medicine (Table 
Table 5. Levels of evidence and classes of recommendations 
 
Clinical level I: high level of 
evidence 
Source a: primary endpoint from random-
ized, double-blind study with sufficient 
sample size
CLASS A 
Consistent level I studies or 
a systematic review (SR) or 
meta analysis (MA)Source b: properly performed meta-analysis of qualitatively outstanding randomized trials
Clinical level II: intermediate level 
of evidence 
Source a: randomized, non-blind studies
CLASS B
Consistent level II studies or 
single level I study
Source b: small randomized trials
Source c: predefined secondary endpoints of 
large randomized trails
Clinical level III: low level of 
evidence
Source a: prospective case series with concur-
rent or historical control CLASS B
Consistent level III studySource b: post hoc analyses of randomized 
trials
Clinical level IV: undetermined 
level of evidence
Source a: small case series without control, 
case reports CLASS CConsistent level III study or
extrapolations from level II or 
III
Source b: general agreement despite the lack 
of scientific evidence from controlled trials
Clinical level V Expert opinion
CLASS D
Level V of evidence or incon-
sistent studies of levels I-IV
5). The main goals in the treatment of MS patients 
should be:
1) improving the speed of recovery from attacks 
(acute treatment, mostly with steroid drugs),
2) reducing the number of attacks or the number of 
MRI lesions, and 
3) attempting to slow progression of the disease (2 
and 3 treatment with disease modifying drugs, 
DMDs). 
Treatment of Relapses
An attack should last for at least 24 h and, accord-
ing to the McDonald criteria there should be expert 
opinion that the event is not a pseudoattack as might 
be caused by an increase in body temperature or infec-
tion. Multiple episodes of paroxysmal symptoms, e.g., 
tonic spasms or trigeminal neuralgia occurring over 
not less than 24 h, may also constitute a relapse. Al-
though the majority of relapses improve to some ex-
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tent, incomplete recovery is an important determinant 
of irreversible neurological impairment in MS at least 
in the earlier stages of MS16-18.
Corticosteroids
There is evidence from several class I studies and 
meta-analyses for a beneficial effect of glucocorticoid 
treatment in MS relapses. Treatment with intravenous 
or oral methylprednisolone in a dose of at least 500 mg 
daily for 5 days should be considered for treatment of 
relapses (level A recommendation). Treatment with i.v. 
methylprednisolone (1 g once daily for 3 days) should 
be considered as an alternative treatment. Treatment 
with i.v. methylprednisolone (1 g once daily for 3 days 
with an oral tapering dose) may be considered for 
treatment of acute optic neuritis (level B recommen-
dation). There is no evidence for major differences in 
the efficacy of methylprednisolone treatment given i.v. 
or orally in terms of clinical efficacy or side effects, but 
prolonged oral treatment may possibly be associated 
with a higher prevalence of side effects. Due to a small 
number of patients included in clinical trials, efficacy 
differences between the i.v. and oral route of admin-
istration cannot be excluded. The optimal dosage, the 
specific glucocorticoid to be used, and whether to use 
a taper after initial pulse therapy, have not been ad-
equately evaluated in randomized, controlled trials. 
These issues should be evaluated in new, randomized 
studies in order to assess the risk/benefit ratios and 
adverse effects of specific glucocorticoids, dose, and 
route of administration for the treatment of MS re-
lapses.
Due to the lack of clinical proofs, there is still the 
need to define patient subgroups that are more likely 
to respond to methylprednisolone treatment. It looks 
like that treatment may be more efficacious in patients 
with clinical, MRI, or CSF evidence (increased my-
elin basic protein concentration in CSF) indicating 
higher disease activity (level C recommendation).
Therapy administration in inpatient or outpatient 
setting has not been addressed in clinical trials, but 
consideration could be given to administering the first 
course of methylprednisolone in inpatient setting due 
to the possible side effects and complications of this 
therapy (good clinical practice).
In patients who fail to respond to therapy with 
methylprednisolone in the previously recommended 
doses, treatment with higher doses (up to 2 g daily for 
5 days) should be considered (level C recommenda-
tion).
Interdisciplinary rehabilitation program should be 
considered after treatment with i.v. methylpredniso-
lone, as evidence from a single trial suggests that it 
probably further improves recovery (level B recom-
mendation)16-19.
Immunoglobulins
There are insufficient data to support the use of in-
travenous immunoglobulin (IVIG) therapy as mono-
therapy for relapses of MS. IVIG has not fulfilled 
the promise indicated by the results of many well-de-
signed studies. Four randomized double-blind studies 
have all shown a beneficial effect on disease activity 
in relapsing-remitting multiple sclerosis (RRMS). 
IVIG 0.15-0.2 g/kg every 4 weeks during 2 years 
showed pronounced reduction in the relapse rate in 
two placebo-controlled trials. A meta-analysis of four 
studies showed significant reduction in the annual re-
lapse rate and disease progression (class I evidence). 
The prevention of relapses with IVIG trial (pRIVIG) 
re-evaluating the effects of IVIG given 0.2 and 0.4 g/
kg monthly failed to show effect on the proportion of 
relapse-free patients and MRI activity in a placebo-
controlled study in 127 patients with RRMS. Thus, 
this trial failed to support earlier observations on a 
beneficial effect of IVIG in RRMS. In secondary pro-
gressive MS, a large placebo-controlled trial of IVIG 
1 g/kg monthly in 318 patients failed to show any 
beneficial effect on the relapse rate, deterioration in 
EDSS, and change in lesion volume of T2 weighted 
images (class I evidence). The only beneficial effect 
was reduction in brain atrophy45. Small studies with 
historical controls suggested that IVIG might reduce 
relapse rate after childbirth (class IV evidence).
IVIG could still be considered as a second- or 
third-line therapy in RRMS if conventional immu-
nomodulatory therapies are not tolerated because of 
side effects or concomitant diseases (level B), and in 
particular in pregnancy where other therapies may not 
be used (good clinical practice point). IVIG cannot be 
recommended for treatment in secondary progressive 
MS (level A). IVIG does not seem to have any valu-
able effect as add-on therapy to methylprednisolone 
for acute exacerbations (level B) and cannot be rec-
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ommended as treatment for chronic symptoms in MS 
(level A). In clinically isolated syndromes and in pri-
mary progressive MS, there is not sufficient evidence 
to make any recommendations16-18.
Plasma Exchange
A single class I crossover study of 22 patients with 
severe relapses of inflammatory demyelination (in-
cluding 12 with MS) who were refractory to treat-
ment with high-dose methylprednisolone suggested a 
beneficial effect of treatment with plasma exchange. 
A Cochrane review and studies of treatment with in-
travenous immunoglobulin (IVIG) have shown that 
prophylactic treatment may result in a decrease in the 
number of relapses in patients with RRMS. A single 
class IV study of IVIG treatment in relapses of MS 
suggested that as many as 68% of patients improved 
within 24 h of treatment. Two recent studies have 
investigated if IVIG treatment as add-on therapy to 
high-dose i.v. methylprednisolone is superior to add-
on placebo treatment (class I study). Both studies were 
negative on primary and secondary end-point.
This treatment option should be restricted to a sub-
group of patients with severe relapses (level B recom-
mendation) or those that have not responded to treat-
ment with corticosteroids. We should have in mind 
the fact that only about one-third of treated patients 
are likely to respond16-18.
Long Term Treatments
First line therapies
Treatment of RRMS must be started with a drug 
with the best risk-benefit ratio. presently, the first line 
drugs regularly used for the treatment of MS include 
glatiramer acetate (Copaxone) 20 mg/day s.c.; IFN 
beta-1a, 30 mg (6 MIU)/week i.m. (Avonex), IFN 
beta-1a, 22 mg three times a week s.c. or 44 mg three 
times a week s.c. (Rebif), IFN beta-1b, 250 mg (9.6 
MIU) every other day s.c. (Betaferon). 
Glatiramer acetate
Glatiramer acetate (GA) is a random polymer 
composed of four amino acids that are found in my-
elin basic protein. It shifts the population of T cells 
from proinflammatory Th1 cells to regulatory Th2 
cells that suppress the inflammatory response. These 
Th2 cells can enter the CNS and inhibit inflammatory 
activity through so called bystander effect as well as 
release of neurotrophins that may exert neuroprotec-
tive effect. There is no evidence for glatiramer acetate 
to have immunosuppressive effects and therefore there 
are no opportunistic infections recorded or neoplastic 
diseases associated with its use. This treatment is con-
sidered safe and there is no need for routine laboratory 
work-up. Side effects of glatiramer acetate usage are 
immediate injection site reactions and post-injection 
syndrome in some patients, as well as lipoatrophy, 
particularly in young women20,21.
Interferon beta
All three interferon beta preparations influence 
inhibition of T cell activation and proliferation in the 
periphery and reduction of T cell passage across the 
blood-brain barrier. There is no evidence for adverse 
immunosuppressive effects of interferon beta. Side ef-
fects mostly present as flu-like symptoms. Monitoring 
of hepatic enzymes and complete blood count should 
be regularly performed (due to possible liver failure 
and leukopenia). There is also some evidence that in-
terferon beta can trigger depression.
Several comparative studies have shown that glati-
ramer acetate and high-dose IFNs are similarly effec-
tive (BEYOND, REGARD study; evidence level 1, 
recommendation grade A)20,21. High IFN doses are 
more effective than low doses (recommendation grade 
B). Glatiramer acetate and IFN are useful at the doses 
mentioned above; final therapeutic decision must be 
made on the basis of available evidence and together 
with the patient, taking into account factors such as 
expected treatment adherence and the potential side 
effects of the drug. A follow-up visit should be sched-
uled at 3-6 months to control the course of the dis-
ease. No treatment change is necessary if patients are 
stable. In some cases, it is necessary to switch medi-
cations or to adjust the dose, either due to treatment 
failure or to the development of severe and/or serious 
adverse events22-27. patients who initially respond to 
IFN but later present with treatment failure must be 
switched from IFN to glatiramer acetate. In patients 
who initially respond to glatiramer acetate and become 
refractory to treatment, IFN should be administered. 
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Neutralizing antibodies (NAbs) are another factor 
associated with treatment failure. The role of NAbs 
on the progression of MS is controversial, and, in 
fact, their determination does not alter therapeutic 
approach. In patients treated with IFN and with per-
sistently high NAbs titers, their determination upon 
treatment failure might play a role28.
The treating neurologist must establish a control 
method to ensure strict compliance with treatment 
(100% adherence), although at present there are no 
studies to determine the best choice. Nurses spe-
cialized in MS should be included in the treatment 
team. 
Second line therapies
If there is a first line treatment failure, the patient 
must be switched to a drug with a higher strength (es-
calation therapy), usually with higher toxicity. Treat-
ing physician must find treatment option at which 
therapeutic effectiveness and side effects have an ‘ac-
ceptable’ ratio29. 
Fingolimod
Fingolimod (sphingosine-1-phosphate) is a recep-
tor antagonist that prevents egress of activated T cells 
from the lymph nodes (shown in clinical trials com-
pared to placebo and interferon beta 1a). Oral therapy 
with fingolimod is an attractive option in correlation 
with natalizumab according to the way of administra-
tion as well as low risk of complications such as pro-
gressive multifocal leukoencephalopathy (pML). The 
drug is registered as first line therapy in the United 
States and as second line therapy in Europe.
Clinical trials were evaluating the impact of fin-
golimod on MS relapses. The first trial demonstrated 
a decrease in the number of relapses, a slowdown of 
disability progression time, reduction in T2 and T1 le-
sion volume and gadolinium enhancing lesion count, 
and a decrease in volume loss. The second trial found 
a lower relapse rate, a decreased number of new lesions 
or decreased size of T2 lesions, less atrophy, and no 
significant differences in terms of progression of dis-
ability among different treatment groups. In the pla-
cebo controlled phase III trial of fingolimod (FREE-
DOMS), tolerability of fingolimod and placebo were 
closely comparable, with a similar proportion of serious 
adverse events and adverse events leading to treatment 
discontinuation. Certain adverse events were more 
common in fingolimod group compared to placebo, i.e. 
back pain, hypertension and bradycardia (the latter two 
attributable to the mechanism of drug action). 
In a trial comparing fingolimod and interferon 
beta 1a, some serious adverse events were recorded. 
Two deaths due to herpetic infections occurred in fin-
golimod group (possibly due to immunosuppressive 
effect, which can facilitate development of opportu-
nistic infections). Skin cancers, both malignant mela-
nomas and malignant basal cell carcinomas, were also 
reported in this trial, therefore special monitoring of 
the skin status should be performed in patients on fin-
golimod therapy.
Experience with this drug is limited and there are 
no long term side effect data available, therefore closer 
and thorough follow up of patients is required than 
with the currently employed drugs. The standard fin-
golimod dosage for treating MS is 0.5 mg taken once 
daily orally (capsules). Studies have shown that doses 
higher than 0.5 mg once daily increase the risk of side 
effects, without improving effectiveness30,31.
Monoclonal antibodies
There are several monoclonal antibodies currently 
used in the treatment of MS that have been approved 
for other indications. All of them have been subject to 
phase II trials and have phase III trials underway or 
planned. Their availability on the market allows for 
off-label uses in patients with especially severe or rap-
idly evolving MS32-34.
The current treatment of choice for escalation 
therapy would be natalizumab, a monoclonal antibody 
directed against the VLA-4 adhesion molecule that 
prevents access of circulating cells to the CNS. Two 
large phase III randomized clinical trials have proven 
natalizumab to be extremely effective in preventing re-
lapses and radiological indices of disease activity in pa-
tients with RRMS35,36. During the treatment with na-
talizumab, the potential adverse events can be present, 
particularly pML caused by reactivation of quiescent 
JC virus infections in the CNS. Before administering 
the drug, the physician must order laboratory tests in-
cluding CD4 and CD8 counts, chest x-ray, and MRI 
scan, as well as evaluation of JC virus serology status in 
order to prevent pML as a neurologic condition of na-
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talizumab therapy. A two-step ELISA immunoassay 
for anti JC virus has been developed, as reported from 
the STRATIFY-1 and STRATIFY-2 studies37.
patients above 60 years of age, those previously 
treated with immunosuppressive agents (a wash-out 
period of at least 6 months must be allowed before 
administering natalizumab), and patients living with 
HIV are at a higher risk of adverse events. Further-
more, experts underscore that both the physician who 
administers the drug and the infusion center must be 
broadly experienced in the management of the drug 
and must be certified for its administration. In the 
event that previous treatments are not effective and 
MRI scans continue to reveal inflammatory activity, 
or if the patient continues to relapse, the neurologist 
may consider escalation to a third level of treatment, 
including the use of drugs not approved for the treat-
ment of MS (off-label indications), such as rituximab 
or alemtuzumab (phase III trials underway), or bone 
marrow transplant. 
Azathioprine
Azathioprine is an immunosuppressant; it sup-
presses proliferation of T and B lymphocytes. This 
drug reduced the number of patients having relaps-
es and disability progression during the first year of 
treatment, and at two- and three-year follow up as 
well. Adverse effects such as gastrointestinal distur-
bances, bone marrow suppression and hepatic toxicity 
occurred frequently; but they were known and antici-
pated and therefore well managed; with drawals due to 
adverse events were few, and mainly due to gastroin-
testinal intolerance. Two studies had deaths reported, 
including four persons in the control group and eight 
in the azathioprine group. These small numbers do 
not allow for statistical analysis. Conflicting conclu-
sions on the potential risk of cancer in MS patients on 
long term azathioprine treatment have been reported 
in eight published papers, not considered in the pres-
ent review because they came from sources other than 
clinical trials. The presence of patients who devel-
oped cancer (3 in azathioprine group and 1 in placebo 
group) was reported in two of five studies. The usual 
dose for treatment of MS patients is 1-3 mg/kg per day 
orally (50 mg tablets)29.
Cyclophosphamide
Cyclophosphamide has been widely studied for the 
treatment of MS and effective stabilization of selected 
patients on this therapy has been suggested in several 
studies. This drug has selective effects on the immune 
response, such as suppression of helper Th1 activity 
and enhancement of helper Th2 responses; both of 
these processes are thought to be involved in the ben-
eficial effect of cyclophosphamide in MS. Over years, 
especially with the advent of MRI, there has been an 
improved understanding of the profound anti-inflam-
matory effect of cyclophosphamide, evidenced by its 
effect on clinical relapses and contrast-enhancing le-
sions on MRI. Toxic effects on urinary bladder and 
the risk of malignancy prevent the widespread use of 
cyclophosphamide in early MS; however, it can be 
dosed safely and is usually well tolerated in actively 
progressing RRMS or early secondary progressive 
MS cases that are unresponsive to beta interferon and 
glatiramer acetate. patients with aggressive MS should 
receive 50 mg/kg/day for four consecutive days. 
There are some alternative protocols with pulse 
doses of cyclophosphamide applied monthly or every 
3 months. Due to toxic effects on urinary bladder dur-
ing therapy with cyclophosphamide, patients should 
receive uromitexan (disodium 2-mercapto ethane 
sulfonate, MESNA), which has been developed as a 
prophylactic agent to prevent urothelial toxicity (hem-
orrhagic cystitis) induced by oxazaphosphorine alky-
lating agents viz. ifosfamide or cyclophosphamide. 
Uromitexan should be administered by intravenous 
injection, usually at doses of 20% of the respective cy-
clophosphamide dose, at times 0 (administration of 
the cytostatic agent), 4 h and 8 h38.
Mitoxantrone 
This drug was for a long time considered as the 
best choice for second line therapy, but it is not safe 
as it was previously thought, as it is associated with a 
high incidence of leukemia (1:135) and cardiomyopa-
thy in treated patients.
A French-British collaboration reported in 1997 
included 42 people with RRMS or secondary progres-
sive MS randomized to receive either a combination 
of mitoxantrone (20 mg i.v. monthly) and the steroid 
methylprednisolone (1 g i.v. monthly), or methylpred-
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nisolone only for six months. In the mitoxantrone 
group, there was a significant reduction in the number 
of relapses and improvement on the EDSS. In a larger 
phase III study known as the MIMS study (Mitoxan-
trone in MS) reported in 2002, 194 people with wors-
ening RRMS or secondary progressive MS received 
placebo, or 5 mg/m2 of mitoxantrone, or 12 mg/m2 
of mitoxantrone administered i.v. every three months 
for 24 months. The higher dose of mitoxantrone was 
shown to be effective and generally well tolerated, re-
ducing the progression of disability and the number of 
relapses compared to placebo. The benefits for those 
assigned to 5 mg/m2 dose were less convincing. Cu-
mulative dose of mitoxantrone should not exceed 120-
140 mg/m2. Different treatment regimens are used in 
different countries according to different regulatory 
demands, but the two regimens most commonly used 
are 12 mg/m2 mitoxantrone i.v. every three months for 
two years (based on the MIMS study) or 20 mg mi-
toxantrone i.v. and 1 g methylprednisolone every four 
weeks for six months (based on the French-British 
study)39,40.
Mycophenolate mofetil
This drug has several proposed mechanisms of 
actions. Animal studies show that it causes a Th1 to 
Th2 shift with an anti-inflammatory profile. It also 
down-regulates MHC class II, chemokines and ad-
hesion related molecules important to inflammation. 
It crosses the blood-brain barrier and may also play a 
neuroprotective role by increasing BDNF.
The first clinical study, ALLEGRO, was a two-
year multi-national, multicenter randomized, double 
blind, placebo-controlled study designed to evaluate 
the efficacy, safety and tolerability of mycopheno-
late mofetil in MS patients (1106 MS patients). The 
second clinical study, BRAVO, is a two-year, multi-
national, multicenter, randomized, double blind, 
parallel-group, placebo-controlled study designed to 
compare the safety, efficacy and tolerability of a once-
daily oral dose of 0.6 mg mycophenolate mofetil ver-
sus placebo and to perform a comparative risk-benefit 
assessment between mycophenolate mofetil and inter-
feron beta-1a. Although comparison of efficacy across 
studies is difficult, the data generally show the relapse 
rate efficacy to be inferior to the injectable interferons 
and glatiramer, but reduction in disability progression 
may be more similar or superior. During the treat-
ment with this drug, side effects such as gastrointes-
tinal symptoms (bleeding, abdominal pain), urinary 
infections, skin rashes, unusual or persistent tiredness 
or weakness, unusual skin lumps or growths, unusual 
weight loss; unusually pale skin, white patches in the 
mouth or throat, yellowing of the skin or eyes (liver 
dysfunction) may occur29.
Treatment of Clinically Isolated Syndrome
At the beginning of the disease course, MS is 
characterized by inflammatory demyelination, which 
may be clinically silent (RIS), therefore patients of-
ten present multiple old inactive lesions on brain and 
spinal cord MRI at the time of the onset of clinical 
symptoms. At the time of first clinical manifestation 
(CIS), neurodegenerative changes are already taking 
place in many patients. The disease then generally 
enters the relapsing-remitting course leading to con-
version to secondary progressive course. Therapeutic 
window for current anti-inflammatory treatments is 
when the inflammatory component is most active. 
CIS episode should be treated with high methyl-
prednisolone doses to reduce the risk of second attack. 
The dose ranges from 500 mg/day for 5 days to 1 g/
day for 3-5 days (evidence level 1, recommendation 
grade A). The administration of 2 g/day for 5 days 
(evidence grade U) has also been described. The total 
dose is administered i.v. during 2-4 hours, and blood 
pressure and heart rate must be monitored to iden-
tify the potential side effects caused by corticosteroids 
such as hypotension at an early stage. In case of severe 
relapses that do not respond to steroid therapy, or in 
case of adverse events, treatment with plasmapheresis 
(recommendation grade B) may be considered. In all 
other cases, there is no evidence to support the use of 
plasmapheresis in the treatment of MS. There is no 
strong evidence in support of the use of natalizumab, 
i.v. immunoglobulin, or a second course of corticoster-
oids during relapses. 
All studies have shown that the administration of 
immunomodulating agents during CIS reduces the 
risk of a second demyelinating episode, without sig-
nificant differences among the different types of im-
munomodulating agents. The criteria for treating CIS 
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with disease-modifying agents are based on the iden-
tification of those patients at a high risk of developing 
MS. Relapses must be treated with the administration 
of high i.v. doses of methylprednisolone. There is no 
strong evidence that the use of oral corticosteroids in-
stead of i.v. methylprednisolone in these cases, as well 
as additional administration of prednisone orally after 
i.v. administration for maintenance purposes and dose 
tapering does not improve the course of relapses. 
It has been proven that the introduction of inter-
feron beta at the time of CIS relatively reduces dis-
ease activity by 40%-60% (CHAMpS study). Early 
treatment with glatiramer acetate is also efficacious in 
delaying conversion to clinically definitive MS in pa-
tients presenting with CIS and brain lesions detected 
by MRI (preCISe study)41-44.
Follow up
In order to evaluate treatment efficacy, once the 
diagnosis is confirmed and treatment has been estab-
lished, first visit must be scheduled in 4-6 weeks and, 
in stable patients, follow up must be made every 3-6 
months. If there are relapses, it is important to note 
duration of relapses, their frequency, severity, and sub-
sequent recovery. Brain and spinal cord MRI during 
relapses is not mandatory (it does not alter the treat-
ment course during acute episodes and is too costly 
for healthcare systems). It is absolutely necessary to 
obtain an MRI scan in cases of an attack in patients 
during treatment with natalizumab (Tysabri), if there 
are new signs or symptoms suggestive of potential side 
effects associated with this drug, particularly pML. 
Table 6. Drugs used in MS relapses and as preventive treatment: first line and second line therapies
Drug name Dosage Level of evidence
Treatment of relapses
Methylprednisolone 0.5-1 g per day i.v.(3-7 days) I
prednisone
0.5-1 mg/kg body weight in tapering 
doses; after 3-6 weeks, 5-10 mg mainte-
nance dose 
IV
IVIG 2.0-0.4 g/kg body weight 2-5 days III
plasma exchange 1-7 times every other day IV
First line therapies
Glatiramer acetate 20 mcg per day I
Interferon beta 1a 
and interferon beta 1b
Avonex 6 MIU once per week, Betaferon 
9.6 MIU every other day, Rebif 22 mcg 
or 44 mcg twice weekly
I
Second line therapies
Fingolimod 0.5 mg per os per day I
Natalizumab 300 mg i.v. every 4 weeks I
Azathioprine 2.5-3 mg/kg body weight per day; 1.5-2.5 maintenance dose II
Cyclophosphamide
1-5 mg/kg twice per day
1 g i.v. every month for 6-12 months, 
then every 5 weeks during 2nd year and 
every 6 weeks during 3rd year of applica-
tion
IV
II
Mitoxantrone
20 mg +1 g methylprednisolone once 
monthly or once in 3 months or 2-3x20 
mg per month followed by 10 mg once in 
3 months till cumulative dose 
I
Mycophenolate mofetil 1 g twice daily IV
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In other patients, the treating physician must evalu-
ate the convenience of administering an MRI during 
relapses based on its severity, the patient’s response to 
Table 7. Drugs used in symptomatic treatment of multiple sclerosis patients
Symptom
Treatment
Pharmacological
Non pharmacologicalDrug Dosage
Spasticity
Baclofen
Tizanidine 
Diazepam 
Gabapentin 
Sativex spray (tetrahydro-
cannabinol 9-THC/Cana-
bidiol CBD ratio 2.7/2.5)*
Botulinum toxin
Intrathecal injection of 
corticosteroids (triamcino-
lone acetonide) 
 Intrathecal baclofen via 
 implantable pump
10-120 mg/day
2-24 mg/day
5-30 mg/day
300-3600 mg/day
max 12 sprays/day
40 mg every 
3rd day up to 6 
times
physiotherapy
Treat concurrent infections
Fatigue
Amantadine
Modafinil
pemoline
200-400 mg/day
200-400 mg/day
37.5-112.5 mg/day
Exclude depression and hypothy-
roidism
physical training and multimodal 
rehabilitation
Lowering body temperature
Pain
(MS related)
Paroxysmal symptoms
Epileptic seizures
Amitriptyline
Carbamazepine
Gabapentin
Lamotrigine
pregabalin
25-150 mg/day
200-1600 mg/day
300-2400 mg/day
200-400 mg/day
150-600 mg/day
physiotherapy
Kinesitherapy
Speech therapy
Bladder symptoms
increased detrusor
activity, urinary incon-
tinence, hyperactive 
bladder
Anticholinergic drugs
Oxybutynin
Tolterodine
Trospium chloride
propiverine
5-20 mg/day divided 
into 2 doses
2-4 mg twice/day
40-60 mg/day
45/day
Acute urinary infection treatment
prophylaxis of recurrent urinary 
infections
Intermittent or continuous urinary 
catheterization
Spastic or dyssynergic 
sphincter 
Nocturnal micturition
Involuntary detrusor 
contractions
Spastic bladder sphinc-
ter
Alpha blockers
Alfuzosin
Tamsulosin
Baclofen
Desmopressin
Oxybutin
Trospium chloride
Capsaicin
Botulinum toxin
0.4 mg/day
0.8 mg/day
10-120 mg/day
20 μg/day intrana-
sally
Intravesical applica-
tion
corticosteroid treatment, and other special circum-
stances of the patient. Disease progression may be 
evaluated based on clinical or paraclinical parameters, 
132 Acta Clin Croat,  Vol. 51,   No. 1,  2012
Vanja Bašić Kes et al. Recommendations for diagnosis and management of multiple sclerosis
Symptom
Treatment
Pharmacological Non pharmacologicalDrug Dosage
Bowel dysfunction Laxatives physioterapy
Sexual dysfunction
Erectile dysfunction
Dyspareunia
Sildenafil 
Alprostadil
Tibolone (estrogen un-
guent) 
25-100 mg 1 h 
before intercourse
Injection into the 
cavernous body of 
penis
Locally
Tremor
Intention
Tremor
Cerebellar
propranolol
Gabapentin
Carbamazepine
Topiramate
Clonazepam
40-120 mg/day
300-2400 mg/day
200-1600 mg/day
25-150 mg/day
3-6 mg/day
Occupational therapy
physiotherapy
VIM thalamotomy
VIM deep brain stimulation
Cognitive dysfunction
Cholinesterase inhibitors
1) physostigmine
2) donepezil
Amantadine
10 mg/day
100 mg twice daily
Attention training
Memory training
Relaxation techniques
Compensational strategies
Dysarthria
Dysphonia
Adductor spasmodic 
dysphonia
Constriction of glottis 
and/or vocal paresis
Botulinum toxin A
Teflon or collagen fluids
Injections locally
Injections locally
Multidisciplinary approach: 
neurologist, otorhinolaryngologist, 
speech therapist
Velum prosthesis
Electronic voice amplifiers
Velopharyngeal surgery
Dysphagia
Functional therapy (muscular func-
tion, swallowing techniques, adapta-
tion of food consistency)
Nasogastric tubes
percutaneous endoscopic gastros-
tomy (pEG)
* not registered in Croatia
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and represents another indicator of treatment fail-
ure. progression of disease should also be evaluated 
by means of EDSS, MSFC, SF 36, VAS and Beck 
depression scale; therefore it is advisable to perform 
them at the onset of the disease in order to have a 
baseline value for comparison with relapses.
Symptomatic Treatment
Besides immunomodulation and immunosuppres-
sion, specific treatment of symptoms is an essential 
component of the overall management of MS patient. 
The aim of symptomatic treatment is to reduce symp-
toms that cause impairment of functional abilities and 
quality of life45.
There is a wide range of different symptoms that 
can appear in MS patient:
– motor function and coordination: spasticity, pare-
ses, ataxia and tremor
– cranial neuralgias, diplopia, nystagmus, dysar-
thria, dysphagia
– autonomic nervous system involvement: bladder 
and bowel dysfunction, sexual dysfunction
– psychiatric and psychological problems: depres-
sion, fatigue, cognitive dysfunctions
– pain and paroxysmal symptoms including epilep-
tic seizures
Centers for Demyelinating Diseases
In order to improve the management of patients 
with demyelinating diseases of the CNS, specialized 
centers should be established. Such centers should in-
clude educated teams who will recognize the symp-
toms of demyelinating diseases at their early stages, 
hospitalize such individuals in order to perform 
differential diagnostic work up and to establish ap-
propriate diagnosis. Furthermore, individuals with 
demyelinating diseases should be followed up, with 
possibilities of acute treatment application at the time 
of relapse as well as introducing preventive treatment. 
Teams should include neurologists, physiotherapists 
and technicians, speech therapists, nurses who will 
educate patients about therapy applications and life-
style modifications, and neuroradiologists, along with 
modern neuroimaging equipment, biochemical labo-
ratory with the possibility of evaluating different ge-
netic testing and biomarkers. As part of such centers, 
there should be the possibility of reproduction coun-
seling as well as counseling on different aspects of the 
disease (symptomatic treatment). Of great importance 
is cooperation with specialized physiotherapy centers 
in order to minimize neurologic sequels of the disease 
and to improve the quality of life of these patients.
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Sažetak
pREpORUKE ZA DIJAGNOSTIKU I LIJEčENJE MULTIpLE SKLEROZE
Vanja Bašić Kes, Iris Zavoreo, Vesna Šerić, Vesna Vargek Solter, Marijan Cesarik, Sanja Hajnšek, Marija Bošnjak Pašić, Tereza 
Adamec, Silvio Bašić Silva Soldo Butković, Ivo Lušić, Lidija Dežmalj Grbelja, Ante Vladić, Ivan Bielen,
Igor Antončić i Vida Demarin
Multipla skleroza (MS) je kronična demijelinizirajuća neurološka bolest koja najčešće pogađa mlade bolesnike (u dobi 
20-50 godina). Oko 85% bolesnika boluje od oblika bolesti obilježenog relapsima i fazama remisije (relapsno remitentni 
oblik bolesti, RRMS). Smjernice za zbrinjavanje bolesnika oboljelih od MS moraju biti usredotočene na tri glavna područ-
ja: a) postavljanje ispravne dijagnoze, b) liječenje relapsa, c) dugotrajno preventivno liječenje uključujući praćenje bolesni-
ka, prilagodbu doze lijeka, po potrebi promjenu lijeka, kontrolu učinka liječenja na progresiju bolesti. Dijagnoza bolesti 
postavlja se na temelju kliničkih i parakliničkih kriterija. posebna je pozornost posvećena lijekovima za liječenje relapsa 
bolesti, lijekovima za preventivno dugoročno liječenje te simptomatskoj terapiji. Kod postavljanja dijagnoze MS treba uzeti 
u obzir diferencijalne dijagnoze. Stoga bi se dijagnoza MS trebala temeljiti na kliničkim i radiološkim dijagnostičkim 
kriterijima, analizi cerebrospinalne tekućine i evociranim potencijalima. 
Ključne riječi: Multipla skleroza – klinička slika, dijagnostički kriteriji, liječenje 

